51. 全身性強皮症 Disease details / Clinical trials / Drug dev / DR info

0.9% sodium chloride
   University College, London
      2015   Phase 2   NCT02551042   United Kingdom
1 infusion OF MSC
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 1/Phase 2   NCT06722105   -
1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid
   Inventiva SA
      2017   Phase 2   EUCTR2015-001617-27-SI   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
      2017   Phase 2   EUCTR2015-001617-27-BG   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
      2015   Phase 2   EUCTR2015-001617-27-DE   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
   Inventiva SAS
      2016   Phase 2   EUCTR2015-001617-27-NL   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
      2015   Phase 2   EUCTR2015-001617-27-IT   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
      2015   Phase 2   EUCTR2015-001617-27-ES   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland
1-22460
   ao. Univ. Prof. Dr. Elisabeth Aberer
      2006   Phase 4   EUCTR2006-000905-41-AT   Austria
10 MG/KG CM-101
   ChemomAb Ltd.
      2024   Phase 2   NCT06210945   United States
10% nitroglycerine IN propylene glycol, USP
   MediQuest Therapeutics, Inc.
      2006   -   EUCTR2005-004979-37-SE   Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-004979-37-GB   Sweden;United Kingdom
2 infusions OF MSC
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 1/Phase 2   NCT06722105   -
2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-OXO-2-propen-1-YL)amino)benzoic acid
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine
3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt
   Vicore Pharma AB
      2019   Phase 2   EUCTR2019-003203-35-GB   United Kingdom
Abatacept
   Dinesh Khanna, MD, MS
      2014   Phase 2   NCT02161406   Canada;United Kingdom;United States
   Stanford University
      2008   Phase 1/Phase 2   NCT00442611   United States
   University of Michigan
      2015   Phase 2   EUCTR2014-005323-27-GB   Canada;Italy;United Kingdom;United States
Abituzumab
   MERCK KGAA
      2016   Phase 2   EUCTR2015-005023-11-IT   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
Abituzumab 1500 MG
   EMD Serono Research & Development Institute, Inc.
      2016   Phase 2   NCT02745145   Argentina;Australia;Canada;Germany;Israel;Italy;Poland;Spain;Turkey;United Kingdom;United States
Abituzumab 500 MG
   EMD Serono Research & Development Institute, Inc.
      2016   Phase 2   NCT02745145   Argentina;Australia;Canada;Germany;Israel;Italy;Poland;Spain;Turkey;United Kingdom;United States
ABR-215757
   Active Biotech AB
      2011   -   EUCTR2011-001667-44-SE   Germany;Sweden;Switzerland
      2011   -   EUCTR2011-001667-44-DE   Germany;Sweden;Switzerland
Acetaminophen
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States
Acetate
   Kuribayashi Shiko
      2024   -   JPRN-jRCTs031200019   -
Acetylcysteine
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy
   Università Politecnica delle Marche
      2007   Phase 2/Phase 3   NCT00428883   Italy
Acetylsalicylic acid
   Federal University of São Paulo
      2018   Phase 4   NCT03558854   Brazil
Achim
   Oslo University Hospital
      2020   Phase 2   NCT04300426   Norway
Achim capsules
   Oslo University Hospital
      2020   Phase 2   EUCTR2019-004400-35-NO   Norway
Acido micofenolico
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
Acotiamide
   Juntendo University School of Medicine
      2018   -   JPRN-UMIN000031901   Japan
ACT-064992
   ACTELION PHARMACEUTICALS LTD.
      2012   -   EUCTR2010-022710-77-IT   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;European Union;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
ACT-293987
   Actelion Pharmaceuticals Ltd
      2014   -   EUCTR2014-000865-34-GB   Germany;United Kingdom
      2014   -   EUCTR2014-000865-34-DE   Germany;United Kingdom
AD26.COV2.S
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Adempas
   Bayer
      2015   Phase 2   NCT02283762   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
ADI-001
   Adicet Therapeutics
      2024   Phase 1   NCT06375993   United States
Administration OF rituximab and methylprednisolone
   University Hospital, Ghent
      2006   Phase 2   NCT00379431   Belgium
Admsc
   University Hospital, Toulouse
      2020   Phase 2   NCT04356755   France
Adsvf application IN THE right hand
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2015   Phase 2   NCT04387825   Mexico
Aimspro
   Daval International Limited
      2008   Phase 2   EUCTR2007-003122-24-GB   United Kingdom
Albumin
   Daval International Limited
      2008   Phase 2   NCT00769028   United Kingdom
Alemtuzumab
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States
Alginic acid
   Khon Kaen University
      2013   Phase 3   NCT01878526   Thailand
Allogeneic hematopoietic stem cell transplantation
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States
Allorx
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05016804   Antigua and Barbuda;Argentina;Mexico
Alpha-2C AR antagonist
   Orion Corporation Orion Pharma
      2011   -   EUCTR2010-024005-13-GB   United Kingdom
Alprostadil
   NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
      2014   Phase 2   NCT02228850   United States
   The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
      2019   Phase 0   ChiCTR2100054434   China
AM-01
   Pharmarama International Limited
      2010   -   EUCTR2009-018194-31-GB   United Kingdom
Ambrisentan
   Heidelberg University
      2014   Phase 2   NCT02290613   Germany
   National Jewish Health
      2012   -   NCT02169752   United States
   Soumya Chatterjee
      2010   -   NCT01072669   United States
   Stanford University
      2008   -   NCT00725361   United States
   Thoraxklinik-Heidelberg gGmbH
      2014   Phase 2   EUCTR2014-001882-28-DE   Germany
   University of California, Los Angeles
      2009   Phase 4   NCT01051960   United States
   University of Pennsylvania
      2010   -   NCT01093885   United States
Amlitelimab
   Scleroderma Research Foundation, Inc.
      2024   Phase 2   NCT06195072   United States
Amlodipine GEL
   Pharmarama International Limited
      2010   -   EUCTR2009-018194-31-GB   United Kingdom
Anaerobically cultivated human intestinal microbiota
   Oslo University Hospital
      2018   Phase 1/Phase 2   NCT03444220   Norway
Anaerobically cultivated medium
   Oslo University Hospital
      2018   Phase 1/Phase 2   NCT03444220   Norway
Anifrolumab
   Ageishi Yuji
      2023   Phase 3   JPRN-jRCT2051230127   Austria;Belgium;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Mexico;Netherlands;Poland;Romania;South Africa;South Korea;Spain;Turkey;United Kingdom;United States of America
   AstraZeneca
      2023   Phase 3   NCT05925803   Austria;Belgium;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Romania;South Africa;Spain;Turkey;United Kingdom;United States;Vietnam
Anti thymocyte globulin
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States
ANTI-CD19 CAR T cell therapy
   Peking University Third Hospital
      2025   Phase 1/Phase 2   NCT06828042   -
   University of Erlangen-Nürnberg Medical School
      2023   Phase 1/Phase 2   NCT06347718   Germany
ANTI-CD19 CAR-NK cells
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2025   -   NCT06614270   China
ANTI-CD19 CAR-T cells
   Peking University Third Hospital
      2025   Phase 1/Phase 2   NCT06821659   -
   The Children's Hospital of Zhejiang University School of Medicine
      2024   Phase 1   NCT06792344   China;Christmas Island
ANTI-CD19-CAR-T cells
   First Affiliated Hospital of Wenzhou Medical University
      2024   Early Phase 1   NCT06420154   China
ANTI-CD19-CD3E-CAR-T cells
   Shanghai Changzheng Hospital
      2024   -   NCT06373081   China
ANTI-CT51 antigen MAB
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
ANTI-human T-lymphocyte immunoglobulin from rabbits
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
ANTI-integrin alphav MAB
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
ANTI-pandemic H1n1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil
ANTI-thymocyte globulin
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
   Fred Hutchinson Cancer Research Center
      2000   Phase 2   NCT00016458   United States
ANTI-thymocyte globulin, rabbit
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
Asasantin retard
   Royal National Hospital for Rheumatic Disease
      2010   Phase 2   EUCTR2009-013468-37-GB   United Kingdom
Aspirin
   Royal National Hospital for Rheumatic Disease
      2010   Phase 2   EUCTR2009-013468-37-GB   United Kingdom
Assigned interventions CD19/bcma CAR T-cells
   Zhejiang University
      2021   Early Phase 1   NCT05085444   China
Atorvastatin
   Robyn T. Domsic, MD, MPH
      2015   Phase 2   NCT02370784   United States
AUC OF MPA measure
   Assistance Publique - Hôpitaux de Paris
      2020   -   NCT04244916   France
Autologous ASC
   CHU de Toulouse
      2020   Phase 2   EUCTR2019-003906-28-FR   France
Autologous hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
Autologous regulatory ?-cells
   Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
      2022   Phase 1/Phase 2   NCT05214014   Belarus
Autologous stem cells
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States
Autologous stemcell transplantation with CD (cluster OF differentiation) 34 selected stem cells
   University Hospital Tuebingen
      2012   Phase 2   NCT01895244   Germany
Avenciguat
   Boehringer Ingelheim
      2022   Phase 2   NCT05559580   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czechia;Denmark;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
AVID200
   Bristol-Myers Squibb
      2019   Phase 1   NCT03831438   United States
Aviptadil
   MONDOGEN AG
      2008   -   EUCTR2007-003621-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
   MondoGEN AG
      2009   -   EUCTR2007-003621-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-003621-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-003621-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
Baricitinib
   Huashan Hospital, Fudan University
      2021   Phase 0   ChiCTR2100041982   China
   Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
      2022   -   ChiCTR2200062190   China
Basic treatment
   Jiangsu Renocell Biotech Company
      2023   Phase 1/Phase 2   NCT06058091   China
BAY63-2521
   Bayer
      2015   Phase 2   NCT02283762   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
BCMA-CD19 CAR-T therapy
   Peking University People's Hospital
      2024   Phase 2   NCT06794008   China
Beam
   University Hospital, Strasbourg, France
      2015   -   NCT02371005   France
Belimumab
   GlaxoSmithKline
      2024   Phase 3   NCT06716606   Argentina;Belgium;Brazil;China;Denmark;Finland;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Spain
      2023   Phase 2/Phase 3   NCT05878717   Argentina;Australia;Belgium;Brazil;Canada;China;Denmark;Finland;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Hospital for Special Surgery, New York
      2019   Phase 2   NCT03844061   United States
      2012   Phase 2   NCT01670565   United States
   Okawa Yasutoshi
      2023   Phase 2-3   JPRN-jRCT2031230153   -
Belumosudil
   Kadmon, a Sanofi Company
      2021   Phase 2   NCT04680975   United States
      2019   Phase 2   NCT03919799   United States
Bendamustine
   Fate Therapeutics
      2024   Phase 1   NCT06308978   United States
Bermekimab
   HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS
      2019   Phase 2   EUCTR2018-004655-20-GR   Greece
   Hellenic Institute for the Study of Sepsis
      2019   Phase 2   NCT04045743   Greece
BH4
   VA Office of Research and Development
      2016   Phase 1/Phase 2   NCT02530996   United States
BI 1015550
   Scleroderma Research Foundation, Inc.
      2024   Phase 2   NCT06195072   United States
Bibf 1120
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2018   Phase 3   EUCTR2016-003403-66-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim AB
      2018   Phase 3   EUCTR2016-003403-66-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim B.V
      2018   Phase 3   EUCTR2016-003403-66-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Ellas SA
      2015   Phase 3   EUCTR2015-000392-28-GR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Boehringer Ingelheim España, S.A.
      2015   Phase 3   EUCTR2015-000392-28-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Boehringer Ingelheim Finland Ky
      2017   Phase 3   EUCTR2015-000392-28-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Fnland Ky
      2018   Phase 3   EUCTR2016-003403-66-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim France
      2015   Phase 3   EUCTR2015-000392-28-FR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Boehringer Ingelheim Limited
      2018   Phase 3   EUCTR2016-003403-66-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000392-28-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Norway KS
      2017   Phase 3   EUCTR2015-000392-28-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2015   Phase 3   EUCTR2015-000392-28-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Portugal, Lda.
      2018   Phase 3   EUCTR2016-003403-66-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co KG
      2018   Phase 3   EUCTR2016-003403-66-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim bv
      2017   Phase 3   EUCTR2016-003403-66-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim España, S.A.
      2018   Phase 3   EUCTR2016-003403-66-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim France
      2018   Phase 3   EUCTR2016-003403-66-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim Pharma GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim RCV GmbH&Co KG
      2016   Phase 3   EUCTR2015-000392-28-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   SCS Boehringer Ingelheim Comm. V
      2018   Phase 3   EUCTR2016-003403-66-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2016   Phase 3   EUCTR2015-000392-28-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
Biobanking with genetic analysis
   University Hospital, Lille
      2020   -   NCT04334031   France
Biopsy
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
   University Hospital, Bordeaux
      2020   -   NCT04265144   France
      2012   -   NCT02562079   France
Biospecimen collection
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
Blood coagulation factor xiii
   University College London (UCL)
      2015   Phase 2   EUCTR2014-001101-40-GB   United Kingdom
Blood sample
   University Hospital, Bordeaux
      2018   -   NCT03575156   France
Blood samples
   Assistance Publique Hopitaux De Marseille
      2018   -   NCT03508375   France
   University Hospital, Bordeaux
      2020   -   NCT04265144   France
      2012   -   NCT02562079   France
Blood sampling
   Medical University Innsbruck
      2019   -   NCT04095351   Austria
   University Hospital, Toulouse
      2022   -   NCT05251415   France
BMS-986020
   Bristol-Myers Squibb
      2016   Phase 2   NCT02588625   Canada;France;Poland;United Kingdom;United States
BNT162b2, bivalent
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Bone marrow transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
Bortezomib
   Northwestern University
      2016   Phase 2   NCT02370693   United States
Bosentan
   ACTELION PHARMACEUTICALS ITALIA
      2005   -   EUCTR2004-000632-82-IT   Italy
      2004   -   EUCTR2004-000631-28-IT   Italy
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   Phase 3   EUCTR2010-021452-26-FR   France
   Actelion
      2011   Phase 4   NCT01395732   Netherlands
      2004   Phase 2/Phase 3   NCT00319033   Canada;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Sweden;Switzerland;United Kingdom;United States
      2003   Phase 2/Phase 3   NCT00070590   France;Germany;Israel;Italy;Netherlands;Sweden;Switzerland;United Kingdom;United States
   Actelion Pharmaceuticals Japan Ltd.
      2013   Phase 3   JPRN-jRCT2080222130   -
   Actelion Pharmaceuticals Nederland bv
      2012   -   EUCTR2011-005303-32-NL   Netherlands
   Assistance Publique - Hôpitaux de Paris
      2010   Phase 2   NCT01241383   France
   Georgetown University
      2006   Phase 2   NCT00377455   United States
   Heinrich-Heine University, Duesseldorf
      2006   Phase 2   NCT00318175   Germany
   Medical University of Graz
      2008   -   NCT00909337   Austria
   Rikshospitalet University Hospital
      2005   Phase 1/Phase 2   NCT00226889   Norway
   University College London
      2005   Phase 2   EUCTR2005-000701-61-GB   United Kingdom
   University Medical Center Groningen
      2015   Phase 4   NCT02480335   Netherlands
Bosentan 125 MG
   Actelion
      2004   Phase 3   NCT00319696   Austria;Canada;France;Germany;Italy;Switzerland;United Kingdom;United States
      2003   Phase 3   NCT02800993   Canada;United States
      2003   Phase 3   NCT00077584   Canada;United States
Bosentan 62.5 MG
   Actelion
      2004   Phase 3   NCT00319696   Austria;Canada;France;Germany;Italy;Switzerland;United Kingdom;United States
      2003   Phase 3   NCT02800993   Canada;United States
      2003   Phase 3   NCT00077584   Canada;United States
Bosentan group
   Elpen Pharmaceutical Co. Inc.
      2016   -   NCT02798055   Greece
Bosentan monohydrate
   Actelion Pharmaceuticals Ltd.
      2004   Phase 3   EUCTR2004-000632-82-GB   Italy;United Kingdom
   University Medical Center Groningen (UMCG)
      2016   -   EUCTR2014-002796-28-NL   Netherlands
Botox® solution
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03717961   France
Botulinum toxin A
   Gunma University Hospital
      2014   -   JPRN-UMIN000017617   Japan
Botulinum toxin type B
   Gunma University
      2016   Phase 2   NCT03007004   Japan
   Gunma University Hospital
      2016   -   JPRN-UMIN000024818   Japan
Brentuximab vedotin
   Lawson Health Research Institute
      2024   Phase 2   NCT05149768   Canada
      2019   Phase 2   NCT03198689   Canada
   National Institute of Allergy and Infectious Diseases (NIAID)
      2017   Phase 1/Phase 2   NCT03222492   Canada;United States
BRL-301
   Bioray Laboratories
      2023   -   NCT05859997   China
Brodalumab
   Kyowa Kirin Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224687   Japan
      2017   Phase 1   JPRN-jRCT2080223630   Japan
Bronchoalveolar samples
   University Hospital, Bordeaux
      2020   -   NCT04265144   France
Buspirone
   Laikon General District Hospital, Athens
      2014   Early Phase 1   NCT02363478   Greece
Busulfan
   New York Medical College
      2007   Phase 1   NCT00684255   United States
C21
   Vicore Pharma AB
      2020   Phase 2   NCT04388176   United Kingdom
      2019   Phase 2   EUCTR2019-003203-35-GB   United Kingdom
C225
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands
CABA-201
   Cabaletta Bio
      2024   Phase 1/Phase 2   NCT06328777   United States
Calcipotriene
   Medical College of Wisconsin
      2016   Phase 1   NCT02680717   -
Calcium channel blockers
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of
CAM2043
   Camurus AB
      2020   Phase 2   EUCTR2019-002444-24-GB   United Kingdom
Campath
   Children's Hospital Los Angeles
      2011   -   NCT01639573   United States
   New York Medical College
      2007   Phase 1   NCT00684255   United States
Capillarema
   OSPEDALE MAGGIORE DI MILANO (IRCCS)
      2006   -   EUCTR2006-005230-20-IT   Italy
CAR-T therapy
   Beijing GoBroad Hospital
      2025   Phase 1   NCT06822881   China
Carbon dioxide
   The Second Xiangya Hospital of Central South University
      2022   -   ChiCTR2200065939   China
CBD OIL
   Khon Kaen University
      2022   Phase 3   NCT05416697   Thailand
CC-4047
   CELGENE CORPORATION
      2012   Phase 2   EUCTR2010-023047-15-IT   Australia;Germany;Italy;Poland;Spain;United Kingdom;United States
   Celgene
      2012   Phase 2   NCT01559129   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-PL   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2010-023047-15-GB   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2010-023047-15-ES   Australia;France;Germany;Italy;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2010-023047-15-DE   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
CC-97540
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2023   Phase 1   NCT05869955   Belgium;France;Germany;Italy;Spain;United States
CC312
   CytoCares Inc
      2024   Early Phase 1   NCT06888960   China
CD19 targeted CAR-T cells
   Chongqing Precision Biotech Co., Ltd
      2023   Phase 1   NCT06056921   China
CD19- bcma CAR-T cells
   Essen Biotech
      2024   Phase 1/Phase 2   NCT06350110   China
CD19-bcma CAR-T cells infusion
   Beijing GoBroad Hospital
      2025   Phase 1/Phase 2   NCT06947460   China
CD19-CAR-DNT cells
   RenJi Hospital
      2023   Phase 1   NCT06316076   China
CD34 selected autologous hematopoietic cells
   University Hospital Tuebingen
      2012   Phase 2   EUCTR2011-002434-40-DE   Germany
CD34+SC
   University Hospital Tuebingen
      2012   Phase 2   EUCTR2011-002434-40-DE   Germany
Cetuximab
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands
Chadox1 NCOV-19
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden
Chemotherapy agents
   Takeda
      2025   Phase 1   NCT06377228   United States
Cialis
   University of Medicine and Dentistry of New Jersey
      2001   Phase 2   NCT00707187   United States
Ciclofosfamide
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
Cilostazol
   AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
      2010   -   EUCTR2010-019977-14-IT   Italy
Clobetasol
   Medical College of Wisconsin
      2016   Phase 1   NCT02680717   -
Clopidogrel
   CHU de Bordeaux
      2021   Phase 2   EUCTR2020-000309-10-FR   France
Clopidogrel treatment
   University Hospital, Bordeaux
      2022   Phase 2/Phase 3   NCT05098704   France
CM-101
   ChemomAb Ltd.
      2019   Phase 1   NCT06037577   Israel
Cmri
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States
CNTY-101
   Century Therapeutics, Inc.
      2025   Phase 1   NCT06255028   United States
CO2 laser
   University of Nebraska
      2024   Early Phase 1   NCT05995626   United States
Comirnaty
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden
Covid-19 vaccine
   Paul R Fortin
      2022   Phase 2/Phase 3   NCT05236491   Canada
Covid-19 vaccine astrazeneca
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden
Covid-19 vaccine moderna
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden
Crefmirlimab
   radboudumc
      2023   Phase 2   EUCTR2022-001484-27-NL   Netherlands
CTX112
   CRISPR Therapeutics
      2025   Phase 1   NCT06925542   Germany;United States
Currently available therapy IN THE community
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   -   NCT00860548   United States
Cutaneous iontophoresis OF treprostinil
   University Hospital, Grenoble
      2012   Phase 1/Phase 2   NCT01554540   France
Cyclophosphamide
   Adicet Therapeutics
      2024   Phase 1   NCT06375993   United States
   Akashi Koichi
      2019   Phase 2   JPRN-jRCTc071190041   Japan
   Assistance Publique - Hôpitaux de Paris
      2013   Phase 3   NCT01570764   France
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States
   David Porter
      2024   Phase 1   NCT06152172   United States
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
   Fate Therapeutics
      2024   Phase 1   NCT06308978   United States
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
   Fred Hutchinson Cancer Research Center
      2000   Phase 2   NCT00016458   United States
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2023   Phase 1   NCT05869955   Belgium;France;Germany;Italy;Spain;United States
   Kyushu University
      2010   Phase 2   JPRN-UMIN000031940   Japan
   M.D. Anderson Cancer Center
      2024   Phase 1/Phase 2   NCT06434363   United States
   Michael Roth
      2009   Phase 2   NCT00883129   United States
   Miltenyi Biomedicine GmbH
      2025   Phase 1   NCT06708845   -
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2/Phase 3   NCT00114530   Canada;United States
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States
   Newcastle upon Tyne NHS Foundation Trust
      2008   Phase 4   EUCTR2008-000224-27-GB   United Kingdom
   Nkarta, Inc.
      2024   Phase 1   NCT06733935   United States
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States
      2011   Phase 3   NCT01445821   United States
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom
   The University of Texas Health Science Center, Houston
      1999   Phase 3   NCT00004563   -
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
   University of Manchester
      2010   -   NCT02339441   -
Cyclophosphamide injection 1G
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom
Dabigatran etexilate
   Medical University of South Carolina
      2016   Phase 1   NCT02426229   United States
Dasatinib
   Bristol-Myers Squibb
      2009   Phase 1/Phase 2   NCT00764309   United States
Depletion OF CD3/CD19 IN AN autologous stem cell transplant
   Stephan Grupp MD PhD
      2025   Phase 2   NCT05029336   United States
Depot leuprolide acetate 3.75 MG
   Joseph Mccune
      2011   Phase 3   NCT01257802   United States
Dersimelagon
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 2   EUCTR2020-000134-17-IT   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Mitsubishi Tanabe Pharma America (MTPA), Inc
      2021   Phase 2   EUCTR2020-000134-17-DE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2021   Phase 2   EUCTR2020-000134-17-BE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000134-17-GB   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States
   Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
      2021   Phase 2   EUCTR2020-000134-17-PL   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
DI-17e6
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
Dietary recommendations
   Coordinación de Investigación en Salud, Mexico
      2017   -   NCT04822038   Mexico
Digna P144 cream
   ISDIN
      2008   -   EUCTR2008-001265-28-HU   Germany;Hungary;Italy;Spain;United Kingdom
      2008   -   EUCTR2008-001265-28-GB   Germany;Hungary;Italy;Spain;United Kingdom
      2008   -   EUCTR2008-001265-28-ES   Germany;Hungary;Italy;Spain;United Kingdom
      2008   -   EUCTR2008-001265-28-DE   Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2007-002015-38-HU   Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 2   EUCTR2007-002015-38-GB   Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2007-002015-38-ES   Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2007-002015-38-DE   Germany;Hungary;Italy;Spain;United Kingdom
   ISDIN S.A.
      2010   -   EUCTR2008-001265-28-IT   Germany;Hungary;Italy;Spain;United Kingdom
Diltiazem
   Mohammad Ali Nazarinia
      2016   Phase 2   NCT02801305   Iran, Islamic Republic of
Dimethyl fumarate
   Robert Lafyatis
      2016   Phase 1   NCT02981082   United States
Diosmin
   Primus Pharmaceuticals
      2024   -   NCT06256575   -
Diphenhydramine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States
Dipyridamole
   Royal National Hospital for Rheumatic Disease
      2010   Phase 2   EUCTR2009-013468-37-GB   United Kingdom
Divalproex sodium
   Yale University
      2014   Phase 1/Phase 2   NCT02166229   United States
Divozilimab
   Biocad
      2022   Phase 3   NCT05726630   Russian Federation
Domperidone
   Khon Kaen University
      2013   Phase 3   NCT01878526   Thailand
Double-blind rituximab
   Tokyo University
      2017   Phase 2/Phase 3   NCT04274257   Japan
DR-0201
   Dren Bio
      2025   Phase 1   NCT06647069   Australia;Bosnia and Herzegovina;Bulgaria;New Zealand;Poland;Serbia;South Africa
Dupilumab
   University of Cologne
      2019   Phase 2   EUCTR2019-002036-90-DE   Germany
Dupilumab 300MG solution FOR injection
   University of Cologne
      2020   Phase 2   NCT04200755   Germany
Efzofitimod 270 MG
   aTyr Pharma, Inc.
      2023   Phase 2   NCT05892614   United States
Efzofitimod 450 MG
   aTyr Pharma, Inc.
      2023   Phase 2   NCT05892614   United States
EMA/chmp/212874/2015
   University Medial Center Groningen
      2018   Phase 4   EUCTR2018-001719-65-NL   Netherlands
EMD 525797
   MERCK KGAA
      2016   Phase 2   EUCTR2015-005023-11-IT   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States
Endoprost
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy
   Azienda ospedaliera universitaria Ospedali Riuniti
      2014   Phase 2   EUCTR2013-004596-12-IT   Italy
Endoprost - 0.05 MG/0.5 ML concentrato PER soluzione PER infusione 1 fiala
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2017   Phase 4   EUCTR2016-002984-32-IT   Italy
Endoprost 0,05MG/0,5ML 1F
   ITALFARMACO
      2005   -   EUCTR2004-002712-28-IT   Italy
Endothelin receptor blocker
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of
Endoxan
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
Erbitux
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands
Esbriet
   InterMune Inc.
      2013   -   EUCTR2013-001353-28-IT   Canada;Italy;United States
EX vivo cultured human mesenchymal stem cells
   University Medical Center Utrecht
      2016   Phase 2   EUCTR2015-000168-32-NL   Netherlands
Factor xiii
   University College, London
      2015   Phase 2   NCT02551042   United Kingdom
Fasudil
   Johns Hopkins University
      2007   Phase 3   NCT00498615   United States
FCR blocker OF autoantibodies
   IRCCS Ospedale San Raffaele
      2024   -   NCT06502678   -
FCR001
   Talaris Therapeutics Inc.
      2021   Phase 1/Phase 2   NCT05098145   United States
FCX-013
   Castle Creek Biosciences, LLC.
      2019   Phase 1/Phase 2   NCT03740724   United States
Fibrogammin® 1250
   University College London (UCL)
      2015   Phase 2   EUCTR2014-001101-40-GB   United Kingdom
Filgrastim
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
   Northwestern University
      2011   Phase 3   NCT01445821   United States
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
Flow cytometry
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
Fludarabine
   Adicet Therapeutics
      2024   Phase 1   NCT06375993   United States
   David Porter
      2024   Phase 1   NCT06152172   United States
   Fate Therapeutics
      2024   Phase 1   NCT06308978   United States
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2023   Phase 1   NCT05869955   Belgium;France;Germany;Italy;Spain;United States
   Miltenyi Biomedicine GmbH
      2025   Phase 1   NCT06708845   -
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States
   New York Medical College
      2007   Phase 1   NCT00684255   United States
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States
      2011   Phase 3   NCT01445821   United States
Fludarabine phosphate
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States
   M.D. Anderson Cancer Center
      2024   Phase 1/Phase 2   NCT06434363   United States
Fresolimumab
   Boston University
      2011   Phase 1   NCT01284322   United States
FT011 100 MG
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine
FT011 200 MG
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine
FT819
   Fate Therapeutics
      2024   Phase 1   NCT06308978   United States
G-CSF
   Akashi Koichi
      2019   Phase 2   JPRN-jRCTc071190041   Japan
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States
   Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
      2007   Phase 1,2   JPRN-UMIN000000589   Japan
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States
G451990
   GALAPAGOS NV
      2019   Phase 2   EUCTR2019-001279-34-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001817-33-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States
   Galapagos NV
      2019   Phase 2   EUCTR2019-001279-34-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001279-34-ES   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001279-34-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001817-33-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001817-33-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001817-33-BE   Belgium;Germany;Italy;Spain;United Kingdom;United States
Gensci048
   Changchun GeneScience Pharmaceutical Co., Ltd.
      2023   Phase 2   NCT06189495   China
Glivec
   AZIENDA OSPEDALIERA S. CARLO
      2007   -   EUCTR2007-001508-19-IT   Italy
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2007   -   EUCTR2007-005322-68-IT   Italy
   ErasmusMC
      2007   -   EUCTR2006-007091-15-NL   Netherlands
   NOVARTIS FARMA
      2008   -   EUCTR2007-004669-17-IT   Italy;United Kingdom
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-GB   Italy;United Kingdom
Glivec 100 MG filmtabletten
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-DE   Germany;Italy;United Kingdom
GLPG1690
   GALAPAGOS NV
      2019   Phase 2   EUCTR2019-001279-34-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001817-33-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States
   Galapagos NV
      2019   Phase 2   NCT03976648   Belgium;Italy;Spain;United Kingdom;United States
      2019   Phase 2   NCT03798366   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001279-34-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001279-34-ES   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001279-34-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001817-33-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001817-33-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001817-33-BE   Belgium;Germany;Italy;Spain;United Kingdom;United States
Glycyrrhizin
   Sumida Hayakazu
      2020   -   JPRN-jRCTs031180366   -
GM-CSF
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States
Granulokine
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
GS-248
   Gesynta Pharma AB
      2020   Phase 2   EUCTR2020-002081-13-PL   Netherlands;Poland;United Kingdom
      2020   Phase 2   EUCTR2020-002081-13-NL   Netherlands;Poland;United Kingdom
      2020   Phase 2   EUCTR2020-002081-13-GB   United Kingdom
      2019   Phase 1   NCT04036227   Sweden
GSK2330811
   GlaxoSmithKline
      2017   Phase 2   NCT03041025   Canada;Netherlands;United Kingdom;United States
      2015   Phase 1   NCT02386436   United Kingdom
GSK2330811 solution FOR injection, 100MG/ML
   GlaxoSmithKline Research & Development Ltd
      2018   Phase 2   EUCTR2016-003417-95-NL   Canada;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003417-95-GB   Netherlands;United Kingdom;United States
Guselkumab dose 1
   Janssen Pharmaceutical K.K.
      2021   Phase 2   NCT04683029   Japan
   Numaguchi Hirotaka
      2021   Phase 2   JPRN-jRCT2051200133   -
Guselkumab dose 2
   Janssen Pharmaceutical K.K.
      2021   Phase 2   NCT04683029   Japan
   Numaguchi Hirotaka
      2021   Phase 2   JPRN-jRCT2051200133   -
Hematopoietic stem cell transplantation
   Richard Burt, MD
      2005   Phase 1   NCT00282425   United States
Herpes zoster vaccine
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Hidonac*EV 1FL 5G 25ML
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy
Hizentra
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom
Hrct
   University of Kansas Medical Center
      2022   -   NCT05204355   United States
Human ANTI-transforming growth factor BETA-1 monoclonal antibody
   Genzyme, a Sanofi Company
      2002   Phase 1/Phase 2   NCT00043706   United States
Human normal immunoglobulin FOR intravenous (IV) administration
   CSL Behring GmbH
      2020   Phase 2   EUCTR2019-000906-31-PL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000906-31-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000906-31-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000906-31-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000906-31-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000906-31-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
Human normal immunoglobulin FOR intravenous administration
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom
Human normal immunoglobulin FOR subcutaneous administration
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom
Hyaluronidase
   University of Nebraska
      2024   Early Phase 1   NCT05995626   United States
Hyaluronidase injected intradermally
   Brigham and Women's Hospital
      2020   Early Phase 1   NCT04656704   -
Hyperimmune caprine serum
   Daval International Limited
      2008   Phase 2   NCT00769028   United Kingdom
Hyperoxia
   University of British Columbia
      2024   -   NCT03800017   Canada
Hyperpolarized XE129
   University of Kansas Medical Center
      2022   -   NCT05204355   United States
HZN-825
   Amgen
      2022   Phase 2   NCT05626751   Argentina;Austria;Chile;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Switzerland;United Kingdom;United States
   HORIZON THERAPEUTICS IRELAND DAC
      2023   Phase 2   EUCTR2021-006271-42-IT   Argentina;Austria;Belgium;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005764-62-IT   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
   Horizon Therapeutics Ireland DAC
      2023   Phase 2   EUCTR2021-006271-42-RO   Argentina;Austria;Belgium;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2021-006271-42-PT   Argentina;Austria;Belgium;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2021-006271-42-PL   Argentina;Austria;Belgium;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2021-006271-42-GR   Argentina;Austria;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2021-006271-42-DE   Argentina;Austria;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2021-006271-42-AT   Argentina;Austria;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2020-005764-62-RO   Argentina;Austria;Chile;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-006271-42-FR   Argentina;Austria;Belgium;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2020-005764-62-PL   Argentina;Austria;Belgium;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2020-005764-62-NL   Argentina;Austria;Belgium;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005764-62-PT   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005764-62-GR   Argentina;Austria;Chile;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005764-62-FR   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005764-62-ES   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005764-62-DE   Argentina;Austria;Chile;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005764-62-AT   Argentina;Austria;Chile;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Switzerland;United Kingdom;United States
HZN-825 BID
   Amgen
      2022   Phase 2   NCT04781543   Argentina;Austria;Chile;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Switzerland;United Kingdom;United States
HZN-825 QD
   Amgen
      2022   Phase 2   NCT04781543   Argentina;Austria;Chile;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Switzerland;United Kingdom;United States
Ianalumab
   Novartis Pharmaceuticals
      2024   Phase 2   NCT06470048   Austria;China;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Poland;Portugal;Spain;Taiwan;Thailand;Turkey;United States;Vietnam
Idrossiclorochina solfato
   UMBERTO I - POLICLINICO DI ROMA
      2022   Phase 3   EUCTR2021-000230-33-IT   Italy
Igpro10
   CSL BEHRING GMBH
      2020   Phase 2   EUCTR2019-000906-31-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom
   CSL Behring
      2019   Phase 2   NCT04138485   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
   CSL Behring GmbH
      2020   Phase 2   EUCTR2019-000906-31-PL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000906-31-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000906-31-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000906-31-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000906-31-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000906-31-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom
Igpro20
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom
Iguratimod
   RenJi Hospital
      2021   -   NCT04515706   -
IL-2
   Century Therapeutics, Inc.
      2025   Phase 1   NCT06255028   United States
IL6 inhibitor
   Assiut University
      2021   Phase 2/Phase 3   NCT05963048   Egypt
Ilomedin
   ao. Univ. Prof. Dr. Elisabeth Aberer
      2006   Phase 4   EUCTR2006-000905-41-AT   Austria
Iloprost
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy
   National Center for Research Resources (NCRR)
      1995   Phase 3   NCT00004786   -
Iloprost injection, FOR intravenous USE
   Eicos Sciences, Inc.
      2019   Phase 3   NCT04040322   United States
      2019   Phase 2   NCT03867097   United States
Iloprost LOW dose
   Charite University, Berlin, Germany
      1997   Phase 2   NCT00622687   Germany
Iloprost sale DI trometamolo
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2017   Phase 4   EUCTR2016-002984-32-IT   Italy
Iloprost therapy UP TO 2 NG/KG X MIN
   Charite University, Berlin, Germany
      1997   Phase 2   NCT00622687   Germany
Iloprost trometamol
   ITALFARMACO
      2005   -   EUCTR2004-002712-28-IT   Italy
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2017   Phase 4   EUCTR2016-002984-32-IT   Italy
Imatinib
   AZIENDA OSPEDALIERA S. CARLO
      2007   -   EUCTR2007-001508-19-IT   Italy
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2007   -   EUCTR2007-005322-68-IT   Italy
   Azienda Ospedaliera Universitaria Policlinico
      2009   Phase 2   NCT00573326   Italy
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-GB   Italy;United Kingdom
      2008   -   EUCTR2007-004669-17-DE   Germany;Italy;United Kingdom
   University of California, Los Angeles
      2007   Phase 1/Phase 2   NCT00512902   United States
Imatinib mesilato
   NOVARTIS FARMA
      2008   -   EUCTR2007-004669-17-IT   Italy;United Kingdom
Imatinib mesylate
   Hospital for Special Surgery, New York
      2007   Phase 2   NCT00555581   United States
   Lawson Health Research Institute
      2008   Phase 2   NCT01545427   Canada
   Lee, Stephanie
      2011   Phase 2   NCT01309997   United States
   Stanford University
      2007   Phase 1/Phase 2   NCT00506831   United States
   University Hospital, Bordeaux
      2007   Phase 2   NCT00479934   France
Imiquimod 5% cream
   The Hospital for Sick Children
      2005   Phase 3   NCT00147771   Canada
Immunoglobulina DI coniglio antitimociti umani
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
Immunoglobulina normale umana PER somministrazione endovenosa
   CSL BEHRING GMBH
      2020   Phase 2   EUCTR2019-000906-31-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom
Immunoglobulina normale umana PER somministrazione sottocutanea
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom
Immunoglobulina umana normale
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom
Imnovid 1 MG hard capsules
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-GB   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2010-023047-15-DE   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
INCB039110
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2020   Phase 2   EUCTR2019-003430-16-FR   France
IND 127861
   radboudumc
      2023   Phase 2   EUCTR2022-001484-27-NL   Netherlands
Indocyanine green
   Duke University
      2017   Phase 4   NCT03155464   -
Inebilizumab
   Kondou Kazuoki
      2022   Phase 3   JPRN-jRCT2031210521   -
Influenza vaccine
   Region Skane
      2011   -   NCT02240888   Sweden
   Tel-Aviv Sourasky Medical Center
      2009   Phase 4   NCT01002508   Israel
Injection OF allogeneic mesenchymal stem cells
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 1/Phase 2   NCT02213705   France
Injection OF autologous stromal vascular fraction
   The Catholic University of Korea
      2016   -   NCT02975960   Korea, Republic of
Intensity-modulated radiation therapy
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States
Interleukin 2
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 2   NCT01988506   France
Intravenous immunoglobulin
   Benesis Corporation
      2006   Phase 3   NCT00348296   Japan
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States
Intravenous infusion
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
   Newcastle upon Tyne NHS Foundation Trust
      2008   Phase 4   EUCTR2008-000224-27-GB   United Kingdom
   Peter Korsten
      2022   -   NCT05204784   Germany
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands
   ao. Univ. Prof. Dr. Elisabeth Aberer
      2006   Phase 4   EUCTR2006-000905-41-AT   Austria
Iontophoresis OF treprostinil
   University Hospital, Grenoble
      2017   Phase 1/Phase 2   NCT03120533   France
Itacitinib
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2020   Phase 2   EUCTR2019-003430-16-FR   France
   Assistance Publique - Hôpitaux de Paris
      2023   Phase 2   NCT04789850   France
IV cyclophosphamide
   Johns Hopkins University
      2001   Phase 3   NCT00501995   United States
IVA337
   Inventiva Pharma
      2015   Phase 2   NCT02503644   Bulgaria;France;Germany;Italy;Netherlands;Poland;Slovenia;Spain;Switzerland;United Kingdom
   Inventiva SA
      2017   Phase 2   EUCTR2015-001617-27-SI   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
      2017   Phase 2   EUCTR2015-001617-27-BG   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
      2015   Phase 2   EUCTR2015-001617-27-GB   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
      2015   Phase 2   EUCTR2015-001617-27-DE   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
   Inventiva SAS
      2016   Phase 2   EUCTR2015-001617-27-NL   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
      2015   Phase 2   EUCTR2015-001617-27-IT   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
      2015   Phase 2   EUCTR2015-001617-27-ES   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland
Ivig
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States
Ixazomib
   Michael M. Pham
      2021   Phase 2   NCT04837131   United States
JBT-101
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
   Corbus Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-PL   Australia;Austria;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2015   Phase 2   NCT02465437   United States
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-NL   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000372-29-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
   Corbus pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-000372-29-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
KHK4827
   Kyowa Kirin Co., Ltd.
      2019   Phase 3   NCT03957681   Japan
      2019   Phase 3   JPRN-jRCT2080224687   Japan
      2017   Phase 1   NCT04368403   Japan
      2017   Phase 1   JPRN-jRCT2080223630   Japan
KYV-101
   David Porter
      2024   Phase 1   NCT06152172   United States
   Kyverna Therapeutics
      2024   Phase 1/Phase 2   NCT06400303   United States
Laboratory biomarker analysis
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
Lactobacillus
   University of Michigan
      2012   Phase 4   NCT01497743   United States
Lanifibranor
   Inventiva SA
      2015   Phase 2   EUCTR2015-001617-27-DE   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom
Lenabasum
   Corbus Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-PL   Australia;Austria;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-NL   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000372-29-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
   Corbus pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-000372-29-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
Lenabasum 20 MG
   Corbus Pharmaceuticals Inc.
      2017   Phase 3   NCT03398837   Australia;Canada;Germany;Israel;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
Lenabasum 20 MG powder IN capsule
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Lenabasum 5 MG
   Corbus Pharmaceuticals Inc.
      2017   Phase 3   NCT03398837   Australia;Canada;Germany;Israel;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
Lenabasum 5 MG powder IN capsule
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Lenabasum 5MG powder IN capsule
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
Leukapheresis
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States
Leukopheresis
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States
Lidocaine 2% without vessel constrictor
   Federal University of São Paulo
      2004   Phase 2/Phase 3   NCT00740285   Brazil
Lipitor
   Salford Royal Hospitals NHS Trust
      2008   Phase 4   EUCTR2005-003775-21-GB   United Kingdom
Liposomal bupivacaine
   Jose Soberon, MD
      2014   Phase 2/Phase 3   NCT02374320   United States
Lymphodepleting chemotherapy
   Century Therapeutics, Inc.
      2025   Phase 1   NCT06255028   United States
Mabthera
   LUMC
      2009   -   EUCTR2008-007180-16-NL   Netherlands
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2013   Phase 2   EUCTR2012-004955-35-IT   Italy
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom
   University Hospital Gent
      2006   Phase 2   EUCTR2006-003836-31-BE   Belgium
Macitentan
   ACTELION PHARMACEUTICALS LTD.
      2012   -   EUCTR2010-022710-77-IT   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;European Union;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
   Actelion Pharmaceuticals Ltd
      2014   -   EUCTR2010-022710-77-CZ   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United Kingdom
      2012   -   EUCTR2010-022969-95-PT   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022969-95-PL   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022969-95-NL   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022969-95-GR   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2010-022969-95-BE   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022710-77-PL   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
      2012   -   EUCTR2010-022710-77-FI   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
      2011   -   EUCTR2010-022969-95-IE   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022969-95-GB   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-022969-95-ES   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-022969-95-DE   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-022710-77-HU   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
      2011   -   EUCTR2010-022710-77-DK   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
      2011   -   EUCTR2010-022710-77-DE   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
      2011   -   EUCTR2010-022710-77-BG   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
Macitentan 10 MG
   Actelion
      2011   Phase 3   NCT01474122   Argentina;Belgium;China;Colombia;Germany;Greece;Ireland;Israel;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
Macitentan 10MG
   Actelion
      2011   Phase 3   NCT01474109   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
Macitentan 3 MG
   Actelion
      2011   Phase 3   NCT01474122   Argentina;Belgium;China;Colombia;Germany;Greece;Ireland;Israel;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
Macitentan 3MG
   Actelion
      2011   Phase 3   NCT01474109   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States
Manual toothbrush
   University Hospital, Strasbourg, France
      2021   -   NCT04627857   France
MEDI-546
   MedImmune LLC
      2009   Phase 1   NCT00930683   United States
MEDI-551
   MedImmune LLC
      2010   Phase 1   NCT00946699   Canada;United Kingdom;United States
Mesenchymal stem cells
   National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
      2025   Phase 1/Phase 2   NCT06888973   Pakistan
   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
      2009   Phase 1/Phase 2   NCT00962923   China
Mesenchymal stem cells from wharton ´S jellyintravenous infusion OF mesenchymal stem cells from wharton ´S jelly
   Universidad de la Sabana
      2021   -   NCT04432545   Colombia
Mesenchymal stromal cells
   UMC Utrecht
      2021   Phase 1/Phase 2   NCT03211793   Netherlands
Mesna
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States
      2011   Phase 3   NCT01445821   United States
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States
Methotrexate
   Beijing Hospital
      2023   Phase 0   ChiCTR2300074825   China
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2020   Phase 0   ChiCTR2000031572   China
   University of California, Los Angeles
      2002   Phase 1/Phase 2   NCT00241189   United States
   University of Manchester
      2010   -   NCT02339441   -
Methylprednisolon
   Radboudumc
      2019   Phase 4   EUCTR2015-004613-24-BE   Belgium;Netherlands
      2016   Phase 4   EUCTR2015-004613-24-NL   Belgium;Netherlands
Methylprednisolone
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States
   Newcastle upon Tyne NHS Foundation Trust
      2008   Phase 4   EUCTR2008-000224-27-GB   United Kingdom
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States
      2011   Phase 3   NCT01445821   United States
   Radboud University
      2017   Early Phase 1   NCT03059979   Netherlands
Methylprednisolone acetate
   Assiut University
      2018   -   NCT03742466   Egypt
Methylprednisolone sodium succinate
   Radboudumc
      2019   Phase 4   EUCTR2015-004613-24-BE   Belgium;Netherlands
      2016   Phase 4   EUCTR2015-004613-24-NL   Belgium;Netherlands
Metoclopramide accord - 10 MG compresse 28 compresse IN blister PVC/pvdc/AL
   MEDAC GMBH
      2016   Phase 3   EUCTR2015-002586-39-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States
Metronidazole
   Coordinación de Investigación en Salud, Mexico
      2015   Phase 4   NCT03692299   Mexico
Mhsct
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2/Phase 3   NCT00114530   Canada;United States
Microgynon
   Boehringer Ingelheim
      2018   Phase 1   NCT03675581   Belgium;France;Germany;Netherlands;Portugal;Spain
Minibody against CD8 conjugated TO desferrioxamine labeled with zirconium ZR 89
   radboudumc
      2023   Phase 2   EUCTR2022-001484-27-NL   Netherlands
Mizoribine
   Faculty of Life Sciences, Kumamoto University
      2010   -   JPRN-UMIN000004162   Japan
MK-2225
   Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
      2023   Phase 1   NCT04948554   Canada;Italy;Switzerland;United States
   Merck Sharp & Dohme LLC
      2023   Phase 1   NCT06643390   United States
MK-7240/PRA023
   Prometheus Biosciences, Inc. a subsidiary of Merck & Co,. Inc. (Rahway, NJ, USA)
      2022   Phase 2   EUCTR2021-005206-10-NL   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc.
      2022   Phase 2   EUCTR2021-005206-10-BE   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc.
      2022   Phase 2   EUCTR2021-005206-10-PL   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, NJ, USA)
      2022   Phase 2   EUCTR2021-005206-10-NO   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005206-10-DE   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
MMF
   Hospital for Special Surgery, New York
      2019   Phase 2   NCT03844061   United States
   Michael Roth
      2017   Phase 2   NCT03221257   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MMF discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MMF maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Moderna MRNA-1273, bivalent
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Monovalent [B.1.351] COV2 pres DTM-AS03
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MPA
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MQX-503
   MediQuest Therapeutics
      2006   Phase 3   NCT00419419   Sweden;United Kingdom;United States
      2006   Phase 2   NCT00378521   United States
   MediQuest Therapeutics, Inc.
      2006   -   EUCTR2005-004979-37-SE   Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-004979-37-GB   Sweden;United Kingdom
MSC
   University Medical Center Utrecht
      2016   Phase 2   EUCTR2015-000168-32-NL   Netherlands
MT-7117
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 2   EUCTR2020-000134-17-IT   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Mitsubishi Tanabe Pharma America (MTPA), Inc
      2021   Phase 2   EUCTR2020-000134-17-DE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Mitsubishi Tanabe Pharma America Inc.
      2021   Phase 2   NCT04440592   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2021   Phase 2   EUCTR2020-000134-17-BE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000134-17-GB   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States
   Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
      2021   Phase 2   EUCTR2020-000134-17-PL   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
MTX
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
   The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
      2019   Phase 0   ChiCTR2100054434   China
MTX discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MTX maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Mycophenolate mofetil
   Boston University
      2006   Phase 1   NCT00433186   United States
   Centre hospitalier de l'Université de Montréal (CHUM)
      2024   Phase 2   NCT05785065   Canada
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States
   Hospital for Special Surgery, New York
      2012   Phase 2   NCT01670565   United States
   Michael Roth
      2017   Phase 2   NCT03221257   United States
      2009   Phase 2   NCT00883129   United States
   Northwestern University
      2016   Phase 2   NCT02370693   United States
   Postgraduate Institute of Medical Education and Research
      2016   Phase 3   NCT02896205   India
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2025   Phase 2   NCT06375005   China
   UMC Utrecht
      2020   Phase 4   EUCTR2019-004718-32-NL   Italy;Netherlands
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
   University of California, San Francisco
      2006   -   NCT00333437   United States
   University of Manchester
      2010   -   NCT02339441   -
Mycophenolate mofetil 500MG
   University College, London
      2021   Phase 2   NCT04927390   United Kingdom
Mycophenolic acid
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
   Region Skane
      2018   -   NCT03678987   Sweden
NAC
   Università Politecnica delle Marche
      2007   Phase 2/Phase 3   NCT00428883   Italy
Nemolizumab
   Maruho Co., Ltd.
      2022   Phase 2   NCT05214794   Japan
   Nishiura Tomoyuki
      2022   Phase 2   JPRN-jRCT2031210481   -
Neovasculgen
   Human Stem Cell Institute, Russia
      2015   Phase 1/Phase 2   NCT02356809   Russian Federation
Neupogen
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
Nilotinib
   Hospital for Special Surgery, New York
      2010   Phase 2   NCT01166139   United States
Nintedanib
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2018   Phase 3   EUCTR2016-003403-66-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim
      2020   -   NCT04325217   Japan
      2018   Phase 1   NCT03675581   Belgium;France;Germany;Netherlands;Portugal;Spain
      2017   Phase 3   NCT03313180   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czechia;Denmark;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   NCT02597933   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim AB
      2018   Phase 3   EUCTR2016-003403-66-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim B.V
      2018   Phase 3   EUCTR2016-003403-66-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Ellas SA
      2015   Phase 3   EUCTR2015-000392-28-GR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Boehringer Ingelheim España, S.A.
      2015   Phase 3   EUCTR2015-000392-28-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Boehringer Ingelheim Finland Ky
      2017   Phase 3   EUCTR2015-000392-28-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Fnland Ky
      2018   Phase 3   EUCTR2016-003403-66-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim France
      2015   Phase 3   EUCTR2015-000392-28-FR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Boehringer Ingelheim Limited
      2018   Phase 3   EUCTR2016-003403-66-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000392-28-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Norway KS
      2017   Phase 3   EUCTR2015-000392-28-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2015   Phase 3   EUCTR2015-000392-28-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Portugal, Lda.
      2018   Phase 3   EUCTR2016-003403-66-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co KG
      2018   Phase 3   EUCTR2016-003403-66-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim bv
      2017   Phase 3   EUCTR2016-003403-66-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim España, S.A.
      2018   Phase 3   EUCTR2016-003403-66-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim France
      2018   Phase 3   EUCTR2016-003403-66-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim Pharma GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim RCV GmbH&Co KG
      2016   Phase 3   EUCTR2015-000392-28-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
      2025   Phase 3   NCT06297096   Poland
   SCS Boehringer Ingelheim Comm. V
      2018   Phase 3   EUCTR2016-003403-66-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2016   Phase 3   EUCTR2015-000392-28-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
Nitric oxide
   Holger Dressel
      2022   -   NCT05505617   Switzerland
Nitroglycerin
   MediQuest Therapeutics
      2007   Phase 3   NCT00577304   United States
      2006   Phase 3   NCT00419419   Sweden;United Kingdom;United States
   Mohammad Ali Nazarinia
      2016   Phase 2   NCT02801305   Iran, Islamic Republic of
Nitroglycerine GEL
   MediQuest Therapeutics, Inc.
      2006   -   EUCTR2005-004979-37-SE   Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-004979-37-GB   Sweden;United Kingdom
Nivolumab
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
NKX019
   Nkarta, Inc.
      2024   Phase 1   NCT06733935   United States
NON applicabile
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2016   Phase 2   EUCTR2016-001028-80-IT   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States
NON propietry, therefore N/A
   Salford Royal Hospitals Trust
      2007   Phase 2   EUCTR2004-002799-41-GB   United Kingdom
None YET
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States
Ofev
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2018   Phase 3   EUCTR2016-003403-66-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim AB
      2018   Phase 3   EUCTR2016-003403-66-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim B.V
      2018   Phase 3   EUCTR2016-003403-66-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Ellas SA
      2015   Phase 3   EUCTR2015-000392-28-GR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Boehringer Ingelheim España, S.A.
      2015   Phase 3   EUCTR2015-000392-28-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Boehringer Ingelheim Finland Ky
      2017   Phase 3   EUCTR2015-000392-28-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Fnland Ky
      2018   Phase 3   EUCTR2016-003403-66-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim France
      2015   Phase 3   EUCTR2015-000392-28-FR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Boehringer Ingelheim Limited
      2018   Phase 3   EUCTR2016-003403-66-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000392-28-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Norway KS
      2017   Phase 3   EUCTR2015-000392-28-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2015   Phase 3   EUCTR2015-000392-28-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim Portugal, Lda.
      2018   Phase 3   EUCTR2016-003403-66-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co KG
      2018   Phase 3   EUCTR2016-003403-66-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2017   Phase 3   EUCTR2015-000392-28-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer Ingelheim bv
      2017   Phase 3   EUCTR2016-003403-66-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim España, S.A.
      2018   Phase 3   EUCTR2016-003403-66-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim France
      2018   Phase 3   EUCTR2016-003403-66-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim Pharma GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Boehringer-Ingelheim RCV GmbH&Co KG
      2016   Phase 3   EUCTR2015-000392-28-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   SCS Boehringer Ingelheim Comm. V
      2018   Phase 3   EUCTR2016-003403-66-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000392-28-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2016   Phase 3   EUCTR2015-000392-28-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States
OL-108
   Beijing GoBroad Hospital
      2025   Phase 1   NCT06980597   China
Omeprazole 20MG
   Khon Kaen University
      2013   Phase 1   NCT03561233   -
Onabotulinumtoxin A
   Johns Hopkins University
      2015   Phase 3   NCT02165111   United States
Ophthalmic emulsion
   Allergan
      2001   Phase 3   NCT00025818   United States
Opsumit 10 MG tablet
   Franz Rischard, DO
      2018   Phase 2/Phase 3   NCT03726398   United States
Oral bovine type I collagen
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2000   Phase 2   NCT00005675   United States
Oral ifetroban
   Cumberland Pharmaceuticals
      2017   Phase 2   NCT02682511   India;United States
Oral treprostinil
   Stanford University
      2016   Phase 2   NCT02663895   United States
Order OF TWO elements OF surgical procedure
   Duke University
      2017   Phase 4   NCT03155464   -
Orencia
   University of Michigan
      2015   Phase 2   EUCTR2014-005323-27-GB   Canada;Italy;United Kingdom;United States
ORM-12471 30MG
   Orion Corporation, Orion Pharma
      2011   Phase 2   NCT01315899   United Kingdom
ORM-12741
   Orion Corporation Orion Pharma
      2011   -   EUCTR2010-024005-13-GB   United Kingdom
Other vasodilator
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of
Oxine
   The First Hospital of Suzhou University
      2024   Phase 1   ChiCTR2500102430   China
Ozone
   Assiut University
      2018   -   NCT03742466   Egypt
      2016   -   NCT02733978   -
Ozone therapy
   Pamukkale University
      2021   -   NCT04826419   Turkey
P-MPA concentration
   Region Skane
      2018   -   NCT03678987   Sweden
P144
   ISDIN
      2007   Phase 2   NCT00574613   Germany;Hungary;Italy;Poland;Spain;United Kingdom
   ISDIN S.A.
      2009   -   EUCTR2007-002015-38-IT   Germany;Hungary;Italy;Spain;United Kingdom
P144 cream
   ISDIN
      2008   Phase 2   NCT00781053   Germany;Hungary;Italy;Poland;Spain;United Kingdom
P144 cytokines inhibitors
   ISDIN
      2008   -   EUCTR2008-001265-28-HU   Germany;Hungary;Italy;Spain;United Kingdom
   ISDIN S.A.
      2010   -   EUCTR2008-001265-28-IT   Germany;Hungary;Italy;Spain;United Kingdom
P144 digna cream
   ISDIN
      2007   Phase 2   EUCTR2007-002015-38-GB   Germany;Hungary;Italy;Spain;United Kingdom
P144. cytokines inhibitors
   ISDIN
      2008   -   EUCTR2008-001265-28-GB   Germany;Hungary;Italy;Spain;United Kingdom
      2008   -   EUCTR2008-001265-28-ES   Germany;Hungary;Italy;Spain;United Kingdom
   ISDIN S.A.
      2010   -   EUCTR2008-001265-28-IT   Germany;Hungary;Italy;Spain;United Kingdom
Paquinimod
   Active Biotech AB
      2011   Phase 2   NCT01487551   Germany;Sweden;Switzerland
      2011   -   EUCTR2011-001667-44-SE   Germany;Sweden;Switzerland
      2011   -   EUCTR2011-001667-44-DE   Germany;Sweden;Switzerland
Part B OPEN-label extension
   Corbus Pharmaceuticals Inc.
      2015   Phase 2   NCT02465437   United States
Patients will BE randomized TO receive EHP-101
   Emerald Health Pharmaceuticals
      2020   Phase 2   NCT04166552   Australia;New Zealand;Puerto Rico;United States
Penicillamine
   Merck Sharp & Dohme Corp.
      2010   -   NCT01374282   -
Peripheral blood stem cell transplantation
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States
Peripheral blood stem cells
   Northwestern University
      2011   Phase 3   NCT01445821   United States
Phosphodiesterase inhibitors
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of
Physalis angulata ethanol extract
   Indonesia University
      2016   -   NCT03141125   Indonesia
Physiological saline
   Gunma University
      2016   Phase 2   NCT03007004   Japan
Pirfenidone
   Beijing Continent Pharmaceutical Co, Ltd.
      2018   Phase 3   NCT03856853   China
   Genentech, Inc.
      2013   Phase 2   NCT01933334   Canada;Italy;United States
   InterMune Inc.
      2013   -   EUCTR2013-001353-28-IT   Canada;Italy;United States
   Michael Roth
      2017   Phase 2   NCT03221257   United States
   RenJi Hospital
      2017   Phase 2/Phase 3   NCT03068234   China
Placentex ® polydeoxyribonucleotide
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy
Placentex ¿ polydeoxyribonucleotide 5.625 MG/3 ML
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy
Platelet GEL
   Università Politecnica delle Marche
      2007   Phase 2/Phase 3   NCT00463125   Italy
Plavix
   CHU de Bordeaux
      2021   Phase 2   EUCTR2020-000309-10-FR   France
Plerixafor
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
Pletal
   AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
      2010   -   EUCTR2010-019977-14-IT   Italy
Polydeoxyribonucleotides
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy
   Mastelli S.r.l
      2016   Phase 4   NCT03388255   Italy
Pomalidomida
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-ES   Australia;France;Germany;Italy;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Pomalidomide
   CELGENE CORPORATION
      2012   Phase 2   EUCTR2010-023047-15-IT   Australia;Germany;Italy;Poland;Spain;United Kingdom;United States
   Celgene
      2012   Phase 2   NCT01559129   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-PL   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2010-023047-15-GB   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2010-023047-15-DE   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
PR1
   University Hospital Zurich
      2010   -   EUCTR2009-017869-27-DE   Germany
PRA023
   Prometheus Biosciences Inc.
      2022   Phase 2   EUCTR2021-005206-10-IT   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Prometheus Biosciences, Inc.
      2022   Phase 2   EUCTR2021-005206-10-HU   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005206-10-ES   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
Prednisolon
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom
Prednisolona
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom
Prednisolone 5 MG
   Prof. Ariane herrick
      2017   Phase 2   NCT03708718   United Kingdom
Prednisolone 5MG gastro-resistant tablets
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom
Prednisolone and taper
   Khon Kaen University
      2018   Phase 2   NCT03607071   Thailand
Prednisoloni
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom
Prednisolonum
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom
Prednisone
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States
Prednizolon
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom
Prednizolonas
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom
PRIM-DJ2727
   The University of Texas Health Science Center, Houston
      2025   Phase 2   NCT06827977   United States
Privigen
   CSL BEHRING GMBH
      2020   Phase 2   EUCTR2019-000906-31-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom
   CSL Behring GmbH
      2020   Phase 2   EUCTR2019-000906-31-PL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000906-31-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000906-31-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000906-31-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000906-31-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000906-31-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom
   Georgetown University
      2013   -   NCT01785056   United States
Prostanoids
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of
Prucalopride succinate
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2013   -   EUCTR2012-005348-92-IT   Italy
Pulmonary function test
   Medical University Innsbruck
      2019   -   NCT04095351   Austria
Pyridostigmine
   Universitair Ziekenhuis Brussel
      2023   Phase 2   NCT06915181   -
Pyridostigmine bromide
   UZ Brussel
      2021   Phase 2   EUCTR2020-004723-17-BE   Belgium
Pyrophosphate
   Szeged University
      2023   -   NCT04966416   -
QAX576
   Novartis Pharmaceuticals
      2007   Phase 2   NCT00581997   United States
Quality-OF-life assessment
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
Questionnaire administration
   Fred Hutchinson Cancer Center
      2011   Phase 2   NCT01413100   Canada;United States
Rabeprazole
   Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University
      2005   -   JPRN-UMIN000020701   Japan
Rapamycin
   University of California, Los Angeles
      2002   Phase 1/Phase 2   NCT00241189   United States
Rapcabtagene autoleucel
   Novartis Pharmaceuticals
      2024   Phase 2   NCT06655896   Australia;France;Germany;Israel;Italy;Japan;Netherlands;Singapore;Spain;Switzerland;Taiwan;United States
Ratg
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States
      2011   Phase 3   NCT01445821   United States
Rbatg
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
RD06-04 cart cell injection
   Nanjing Bioheng Biotech Co., Ltd.
      2024   Early Phase 1   NCT06549296   China
RD06-04 or RD06-05 cart cell injection
   Nanjing Bioheng Biotech Co., Ltd.
      2024   Early Phase 1   NCT06548607   China
RD06-05 cart cell injection
   Nanjing Bioheng Biotech Co., Ltd.
      2025   Early Phase 1   NCT06775912   China
Recombinant humanized ANTI-human monoclonal antibody directed against THE IL-6R
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States
Reduced intensity allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
Reduced intensity allogeneic transplant
   New York Medical College
      2007   Phase 1   NCT00684255   United States
Relaxin
   National Center for Research Resources (NCRR)
      1991   Phase 2   NCT00004380   -
   University of Medicine and Dentistry of New Jersey
      1998   Phase 3   NCT00704665   -
Relma-CEL
   Liangjing Lu
      2024   Phase 1   NCT06414135   China
Resolor*28CPR RIV 2MG
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2013   -   EUCTR2012-005348-92-IT   Italy
Resunab, ajulemic acid, anabasum
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
   Corbus Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-PL   Australia;Austria;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-NL   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000372-29-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
   Corbus pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-000372-29-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
Rheopheresis treatment
   Peter Korsten
      2022   -   NCT05204784   Germany
RIC allobmt W ptcy IN refractory SSC
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2022   Phase 1   NCT05298358   United States
Rilonacept
   Boston University
      2011   Phase 1/Phase 2   NCT01538719   United States
Ringer lactate
   Assistance Publique Hopitaux De Marseille
      2017   Phase 2   NCT02866552   France
      2015   Phase 2   NCT02558543   France
Riocigu
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
Riociguat
   Bayer
      2015   Phase 2   NCT02283762   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
   Dinesh Khanna, MD, MS
      2016   Phase 2   NCT02915835   United States
Riociguat coated tablet 0.5 MG
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
Riociguat coated tablet 1.0 MG
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
Riociguat coated tablet 1.5 MG
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
Riociguat coated tablet 2.0 MG
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
Riociguat coated tablet 2.5 M
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
Riociguat coated tablet 2.5 MG
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
Riociguat oral tablet
   Heidelberg University
      2022   Phase 2   NCT05339087   Austria;France;Germany;Italy;Switzerland;United Kingdom
Rituximab
   Assistance Publique - Hôpitaux de Paris
      2013   Phase 2/Phase 3   NCT01748084   France
   Assiut University
      2021   Phase 2/Phase 3   NCT05963048   Egypt
   Department of Dermatology, The University of Tokyo
      2012   -   JPRN-UMIN000007702   Japan
   Department of Rheumatology and immunology, Huashan Hospital, Fudan University
      2023   Phase 4   ChiCTR2300076972   China
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States
   Hospital for Special Surgery, New York
      2019   Phase 2   NCT03844061   United States
   LUMC
      2009   -   EUCTR2008-007180-16-NL   Netherlands
   Lee, Stephanie
      2011   Phase 2   NCT01309997   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States
   Novartis Pharmaceuticals
      2024   Phase 2   NCT06655896   Australia;France;Germany;Israel;Italy;Japan;Netherlands;Singapore;Spain;Switzerland;Taiwan;United States
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom
   University Hospital Gent
      2006   Phase 2   EUCTR2006-003836-31-BE   Belgium
   University Hospital, Ghent
      2009   Phase 2   NCT00936546   Belgium
   University Hospital, Tours
      2024   Phase 3   NCT06549231   -
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan
   Yoshizaki Ayumi
      2012   Phase 2   JPRN-jRCTs031180373   -
RO 47-0203
   Actelion Pharmaceuticals Ltd.
      2004   Phase 3   EUCTR2004-000632-82-GB   Italy;United Kingdom
RO 487-7533/F10-04
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States
RO487-7533/F10-04
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 3   EUCTR2015-000424-28-IT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2016   Phase 3   EUCTR2015-000424-28-IE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000424-28-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-LT   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-HR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-DK   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
RO7303509
   Genentech, Inc.
      2023   Phase 1   NCT05462522   Argentina;Belgium;France;Germany;Israel;Poland;Portugal;Puerto Rico;Serbia;Spain;United Kingdom;United States
Roactemra
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States
   Hoffmann-La Roche
      2012   Phase 3   NCT01532869   Canada;France;Germany;United Kingdom;United States
Roactemra - 162 MG - soluzione iniettabile - USO sottocutaneo - siringa preriempita 0,9ML (vetro) - 4 siringhe preriempite
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 3   EUCTR2015-000424-28-IT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
Roactemra 162 MG
   F. Hoffmann-La Roche Ltd
      2016   Phase 3   EUCTR2015-000424-28-IE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000424-28-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-LT   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-HR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-DK   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
Rosemary essential OIL
   ARCIM Institute Academic Research in Complementary and Integrative Medicine
      2015   -   NCT03531216   Germany
Rosuvastatin
   Faculty of Medicine, University of Alexandria
      2008   Phase 3   NCT00984932   Egypt
Ry_sw01 cell injection
   Jiangsu Renocell Biotech Company
      2023   Phase 1/Phase 2   NCT06058091   China
   The First Hospital of Suzhou University
      2024   Phase 1   ChiCTR2500102430   China
Saccharomyces boulardii oral tablet
   Coordinación de Investigación en Salud, Mexico
      2015   Phase 4   NCT03692299   Mexico
SAR100842
   SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT
      2013   -   EUCTR2012-001369-34-IT   Canada;Germany;Italy;Switzerland;United Kingdom;United States
   Sanofi
      2013   Phase 2   NCT01651143   France;Germany;Italy;Switzerland;United Kingdom;United States
   Sanofi-aventis recherche & développement
      2012   Phase 2   EUCTR2012-001369-34-GB   Canada;Germany;Italy;Switzerland;United Kingdom;United States
      2012   -   EUCTR2012-001369-34-DE   Canada;Germany;Switzerland;United Kingdom;United States
SAR156597
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2016   Phase 2   EUCTR2016-001028-80-IT   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States
   Sanofi
      2016   Phase 2   NCT02921971   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States
   sanofi-aventis recherche & développement
      2016   Phase 2   EUCTR2016-001028-80-EE   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2016-001028-80-DE   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2016-001028-80-BE   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2016-001028-80-AT   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;United Kingdom;United States
SAR231893
   University of Cologne
      2019   Phase 2   EUCTR2019-002036-90-DE   Germany
Selexipag
   Actelion
      2014   Phase 2   NCT02260557   France;Germany;United Kingdom
   Actelion Pharmaceuticals Ltd
      2014   -   EUCTR2014-000865-34-GB   Germany;United Kingdom
      2014   -   EUCTR2014-000865-34-DE   Germany;United Kingdom
Self bone marrow transplant
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States
Semaglutide PEN injector
   Second Xiangya Hospital of Central South University
      2024   Phase 1   NCT06149260   China
Serial night time position splint
   Federal University of São Paulo
      2010   Phase 3   NCT01586663   Brazil
SF-12 questionnaire
   University Hospital, Lille
      2020   -   NCT04334031   France
Sildenafil
   Johns Hopkins University
      2021   Phase 2   NCT04797286   United States
   Topadur Pharma AG
      2025   Phase 2   NCT06954597   France
   University Hospital, Lille
      2010   Phase 3   NCT01295736   France
Sildenafil 20MG and bosentan 62.5MG
   Postgraduate Institute of Medical Education and Research
      2016   Phase 4   NCT03053739   India
Sildenafil citrate
   Federal University of São Paulo
      2011   Phase 3   NCT01347008   Brazil
Sildenafil therapy
   Charite University, Berlin, Germany
      2004   Phase 2   NCT00624273   Germany
Simvastatin
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-006035-32-IT   Italy
Sinvacor*28CPR RIV 20MG
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-006035-32-IT   Italy
Sirolimus
   Goto Mizuki
      2023   Phase 1-2   JPRN-jRCT2071220063   -
   Peking University People's Hospital
      2018   Phase 2   NCT03365869   -
   The First Affiliated Hospital of China Medical University
      2020   Phase 0   ChiCTR2000030370   China
Sodium chloride
   Radboud University
      2017   Early Phase 1   NCT03059979   Netherlands
Sodium chloride solution
   Oslo University Hospital
      2020   Phase 2   EUCTR2019-004400-35-NO   Norway
Sodium fluoride 18F
   University Medial Center Groningen
      2018   Phase 4   EUCTR2018-001719-65-NL   Netherlands
Sodium nitroprusside
   Salford Royal Hospitals Trust
      2007   Phase 2   EUCTR2004-002799-41-GB   United Kingdom
Sodium thiosulfate
   Robyn T. Domsic, MD, MPH
      2025   Phase 2   NCT06672822   United States
Sodium thiosulfate pentahydrate
   CHU de LIMOGES
      2019   Phase 2   EUCTR2018-001978-22-FR   France
SOLU-medrol
   Radboudumc
      2019   Phase 4   EUCTR2015-004613-24-BE   Belgium;Netherlands
SOLU-medrone
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
   Newcastle upon Tyne NHS Foundation Trust
      2008   Phase 4   EUCTR2008-000224-27-GB   United Kingdom
Soluble VE cadherin
   University Hospital, Grenoble
      2014   -   NCT02212249   France
Sonic toothbrush
   University Hospital, Strasbourg, France
      2021   -   NCT04627857   France
Standard lymphodepletion regimen
   Kyverna Therapeutics
      2024   Phase 1/Phase 2   NCT06400303   United States
Standard therapy
   Department of Rheumatology and immunology, Huashan Hospital, Fudan University
      2023   Phase 4   ChiCTR2300076972   China
   National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
      2025   Phase 3   NCT06297096   Poland
Standard treatment according TO THE clinical protocols
   Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
      2022   Phase 1/Phase 2   NCT05214014   Belarus
Stem cell transplantation
   Northwestern University
      2005   Phase 2   NCT00278525   United States
Sterile saline solution
   Johns Hopkins University
      2015   Phase 3   NCT02165111   United States
Steroids
   RenJi Hospital
      2017   Phase 2/Phase 3   NCT03068234   China
STI571
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-GB   Italy;United Kingdom
      2008   -   EUCTR2007-004669-17-DE   Germany;Italy;United Kingdom
   Novartis Pharmaceuticals
      2008   Phase 2   NCT00613171   Germany;Italy;Switzerland;United Kingdom;United States
STK-009
   Synthekine
      2025   Phase 1   NCT06544330   United States
Stromal vascular fraction
   Assistance Publique Hopitaux De Marseille
      2017   Phase 2   NCT02866552   France
      2015   Phase 2   NCT02558543   France
STS
   Robyn T. Domsic, MD, MPH
      2025   Phase 2   NCT06672822   United States
   University Hospital, Limoges
      2020   Phase 2   NCT03582800   France
Study OF THE gene expression profile
   Assistance Publique Hopitaux De Marseille
      2018   -   NCT03629002   France
Syncar-001
   Synthekine
      2025   Phase 1   NCT06544330   United States
T cell injection targeting CD19 chimeric antigen receptor
   PersonGen BioTherapeutics (Suzhou) Co., Ltd.
      2024   Early Phase 1   NCT06417398   -
      2024   -   NCT06361745   China
T cell injection targeting CD7 chimeric antigen receptor
   PersonGen BioTherapeutics (Suzhou) Co., Ltd.
      2025   -   NCT06871644   China
Tacrolimus
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States
   Medical College of Wisconsin
      2016   Phase 1   NCT02680717   -
   The First Affiliated Hospital of Guangzhou University of Chinese Medicine
      2021   Phase 0   ChiCTR2100042327   China
Tadalafil
   Sanjay Gandhi Postgraduate Institute of Medical Sciences
      2012   Phase 3   NCT01553981   India
      2009   Phase 3   NCT01117298   India
      2007   Phase 3   NCT00626665   -
Tadalafil and ambrisentan upfront combination therapy
   Johns Hopkins University
      2010   Phase 4   NCT01042158   United States
Tafasitamab
   M.D. Anderson Cancer Center
      2024   Phase 1/Phase 2   NCT06434363   United States
TAK-007
   Takeda
      2025   Phase 1   NCT06377228   United States
Telitacicept
   Ningbo Medical Center Lihuili Hospital
      2022   Phase 4   ChiCTR2400085742   China
   Peking University Third Hospital
      2024   Phase 4   NCT06546540   China
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2025   Phase 2   NCT06375005   China
Temanogrel
   Arena Pharmaceuticals
      2021   Phase 2   NCT04915950   United Kingdom;United States
Tepezza
   Amgen
      2021   Phase 1   NCT04478994   United States
Terguride
   University Hospital Zurich
      2010   -   EUCTR2009-017869-27-DE   Germany
Terguride hydrogenmaleate
   MEDAC GMBH
      2016   Phase 3   EUCTR2015-002586-39-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States
   medac GmbH
      2017   Phase 3   EUCTR2015-002586-39-BE   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002586-39-PT   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002586-39-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002586-39-GB   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002586-39-FR   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002586-39-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States
TGF-beta receptor TYPE-2 extracellular domain fused TO human IGG1 FC domain
   ACCELERON PHARMA INC.
      2022   Phase 1;Phase 2   EUCTR2021-001004-15-IT   Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
TGF-beta receptor TYPE-2 fused TO human IGG1 FC domain
   ACCELERON PHARMA INC.
      2022   Phase 1;Phase 2   EUCTR2021-001004-15-IT   Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
TGF-beta recettore DI T
   ACCELERON PHARMA INC.
      2022   Phase 1;Phase 2   EUCTR2021-001004-15-IT   Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
TGF-beta recettore DI tipo II extracellulare, collegata A UN dominio FC umano modificato dell’immuno
   ACCELERON PHARMA INC.
      2022   Phase 1;Phase 2   EUCTR2021-001004-15-IT   Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Thalidomide
   New York University School of Medicine
      2000   Phase 1   NCT00418132   United States
Thiotepa
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States
Thymoglobulin
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
Thymoglobuline
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom
Thymoglobuline - 5 MG/ML polvere PER concentrato PER soluzione PER infusione 1 fiala DA 10 ML
   UNIVERSITY MEDICAL CENTER UTRECHT
      2022   Phase 4   EUCTR2019-004718-32-IT   Belgium;Croatia;Germany;Italy;Netherlands;Sweden
Tibulizumab
   Zura Bio Inc
      2025   Phase 2   NCT06843239   United States
TM5614
   Asano Yoshihide
      2023   Phase 2   JPRN-jRCT2021230022   -
Tocilizumab
   CHUGAI PHARMACEUTICAL CO., LTD
      2017   Phase 3   JPRN-jRCT2080223704   Japan
   Chugai Pharmaceutical Co., Ltd.
      2016   Phase 3   JPRN-jRCT2080222911   25 countries including Japan, US, UK, Germany etc.;Europe;Japan;North America
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 3   EUCTR2015-000424-28-IT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2016   Phase 3   EUCTR2015-000424-28-IE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000424-28-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-LT   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-HR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-DK   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000424-28-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States
   Hoffmann-La Roche
      2015   Phase 3   NCT02453256   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;South Africa;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   NCT01532869   Canada;France;Germany;United Kingdom;United States
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2023   Phase 1   NCT05869955   Belgium;France;Germany;Italy;Spain;United States
   Kanazawa University Hospital
      2016   -   JPRN-UMIN000022624   Japan
   Kanazawa University Hospital, Department of dermatology
      2015   -   JPRN-UMIN000020389   Japan
   National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
      2025   Phase 3   NCT06297096   Poland
   Osaka University
      2014   -   JPRN-UMIN000015495   Japan
   Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine
      2011   Phase 2   JPRN-UMIN000005550   Japan
   The First Affiliated Hospital of Wenzhou Medical University
      2025   -   ChiCTR2500097181   China
   The University of Tokyo
      2013   -   JPRN-UMIN000012214   Japan
   Yoshizaki Ayumi
      2013   Phase 2   JPRN-jRCTs031180370   -
Tofacitinib
   Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
      2023   Phase 2   NCT06044844   Bangladesh
   The Second Hospital of Shanxi Medical University
      2022   Phase 0   ChiCTR2300074515   China
   University of Michigan
      2017   Phase 1/Phase 2   NCT03274076   United States
TOP-N53 vehicle
   Topadur Pharma AG
      2025   Phase 2   NCT06954597   France
Topical amphimatrix
   MediQuest Therapeutics
      2007   Phase 3   NCT00577304   United States
      2006   Phase 3   NCT00419419   Sweden;United Kingdom;United States
Topical calcipotriene 0.005% ointment
   Northwestern University
      2015   -   NCT02411643   United States
Topical organogel with nitroglycerin
   MediQuest Therapeutics
      2004   Phase 2/Phase 3   NCT00253331   United States
Total body irradiation
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States
Total-body irradiation
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States
Tracleer
   ACTELION PHARMACEUTICALS ITALIA
      2004   -   EUCTR2004-000631-28-IT   Italy
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   Phase 3   EUCTR2010-021452-26-FR   France
   Actelion Pharmaceuticals Ltd.
      2004   Phase 3   EUCTR2004-000632-82-GB   Italy;United Kingdom
   Actelion Pharmaceuticals Nederland bv
      2012   -   EUCTR2011-005303-32-NL   Netherlands
   Heinrich-Heine University, Duesseldorf
      2006   Phase 2   NCT00318175   Germany
   University College London
      2005   Phase 2   EUCTR2005-000701-61-GB   United Kingdom
   University Medical Center Groningen (UMCG)
      2016   -   EUCTR2014-002796-28-NL   Netherlands
Tracleer*56CPR RIV 125MG
   ACTELION PHARMACEUTICALS ITALIA
      2005   -   EUCTR2004-000632-82-IT   Italy
Transdihydrolisuride
   University Hospital Zurich
      2010   -   EUCTR2009-017869-27-DE   Germany
Treprostinil diethanolamine
   United Therapeutics
      2009   Phase 2   NCT00848107   Canada;United Kingdom;United States
      2009   Phase 2   NCT00775463   Canada;United Kingdom;United States
      2008   Phase 1   NCT00848939   United States
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States
      2009   -   EUCTR2008-005018-39-GB   United Kingdom
Treprostinil sodium
   Camurus AB
      2020   Phase 2   EUCTR2019-002444-24-GB   United Kingdom
Trimebutine
   Third Department of Internal Medicine (Department of Rheumatology) Shimane University Faculty of Medicine
      2017   Phase 3   JPRN-UMIN000026859   Japan
Tulisokibart
   Prometheus Biosciences, Inc.
      2022   Phase 2   EUCTR2021-005206-10-HU   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Prometheus Biosciences, Inc. a subsidiary of Merck & Co,. Inc. (Rahway, NJ, USA)
      2022   Phase 2   EUCTR2021-005206-10-NL   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc.
      2022   Phase 2   EUCTR2021-005206-10-PL   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, NJ, USA)
      2022   Phase 2   EUCTR2021-005206-10-NO   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005206-10-DE   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
      2022   Phase 2   NCT05270668   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
Tulisokibart
   Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc.
      2022   Phase 2   EUCTR2021-005206-10-BE   Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
Ucar T-cell
   Institute of Hematology & Blood Diseases Hospital, China
      2025   Phase 1   NCT06941129   China
Ucmsc
   Marie Hudson, MD
      2023   Phase 1/Phase 2   NCT04356287   Canada
Umbilical cord blood CD19-bcma CAR-T cells infusion
   Beijing GoBroad Hospital
      2025   Phase 1/Phase 2   NCT06947473   -
Urine sample
   University Hospital, Bordeaux
      2018   -   NCT03575156   France
UT-15 SR
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States
UT-15C SR
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States
      2009   -   EUCTR2008-005018-39-GB   United Kingdom
UT-15C-SR
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States
      2009   -   EUCTR2008-005018-39-GB   United Kingdom
UTAA91 injection
   PersonGen BioTherapeutics (Suzhou) Co., Ltd.
      2025   Early Phase 1   NCT06982534   China
      2025   Early Phase 1   NCT06970951   China
Uvadex
   London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
      2025   Phase 2   NCT04986605   Canada
Vaccination with 2 doses OF shingrix vaccine
   Region Skane
      2024   Phase 4   NCT06763783   Sweden
Vasculopathy assessment
   VA Office of Research and Development
      2016   Phase 1/Phase 2   NCT02530996   United States
Vaseline
   Mohammad Ali Nazarinia
      2016   Phase 2   NCT02801305   Iran, Islamic Republic of
Veledimex
   Castle Creek Biosciences, LLC.
      2019   Phase 1/Phase 2   NCT03740724   United States
VIB7734
   Amgen
      2018   Phase 1   NCT03817424   Poland;Spain;United States
VIP
   MONDOGEN AG
      2008   -   EUCTR2007-003621-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
   MondoGEN AG
      2009   -   EUCTR2007-003621-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-003621-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-003621-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
Vitamin D3
   Coordinación de Investigación en Salud, Mexico
      2017   -   NCT04822038   Mexico
Vivomixx probiotics
   Singapore General Hospital
      2013   Phase 2   NCT01804959   Singapore
Vixarelimab
   Genentech, Inc.
      2023   Phase 2   NCT05785624   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;New Zealand;Poland;South Africa;Spain;Taiwan;United States
Volibris
   Thoraxklinik-Heidelberg gGmbH
      2014   Phase 2   EUCTR2014-001882-28-DE   Germany
Vunakizumab
   The Second Xiangya Hospital, Central South University
      2025   -   ChiCTR2500097140   China
Water
   University Hospital, Strasbourg, France
      2021   -   NCT04627857   France
Yellow fever vaccine
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil
YTS109 cell
   China Immunotech (Beijing) Biotechnology Co., Ltd.
      2025   Phase 1   NCT06978647   -
Zamtocabtagene autoleucel
   Miltenyi Biomedicine GmbH
      2025   Phase 1   NCT06708845   -
ZD4054
   University College London
      2014   Phase 2   EUCTR2013-003200-39-GB   United Kingdom
Zibotentan
   University College London
      2014   Phase 2   EUCTR2013-003200-39-GB   United Kingdom
   University College, London
      2014   Phase 2   NCT02047708   United Kingdom
Ziritaxestat
   Galapagos NV
      2019   Phase 2   EUCTR2019-001279-34-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States